Relay Therapeutics (RLAY) Price & Analysis

Compare

501 Followers

RLAY Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.78 - $10.72

Previous CloseN/A

Volume391.09K

Average Volume (3M)2.41M

Market Cap

$577.58M

Enterprise Value-$30.02M

Total Cash (Recent Filing)$93.54M

Total Debt (Recent Filing)$47.16M

Price to Earnings (P/E)―

Beta2.31

Next Earnings

Nov 05, 2025

EPS Estimate

-0.43

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.41

Shares Outstanding172,411,400

10 Day Avg. Volume2,534,570

30 Day Avg. Volume2,412,923

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap-0.05

Enterprise Value/Revenue-3.91

Enterprise Value/Gross Profit32.17

Enterprise Value/Ebitda0.08

Forecast

1Y Price Target

$11.44

Price Target Upside252.00% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering11

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThere is optimism about the success of the Ph3 trial due to robust data from previous studies, indicating potential positive outcomes.

Financial StabilityRelay Therapeutics has a strong cash position of $657M, providing financial stability and supporting operations into 2029.

Strategic ActionsStrategic cost reductions make sense and are viewed as a positive for the stock.

Bears Say

Price Target AdjustmentThe price target has been adjusted to $12 from a previous target of $14.

Stock PerformanceThe stock is down -20% vs XBI -8% YTD, likely due to a lack of clinical catalysts in the upcoming 12 months and macro.

Workforce ReductionRelay announced it is reducing the workforce by ~70 people, resulting in a total decrease in the company's annual research budget by ~75%.

Relay Therapeutics News

Relay Therapeutics price target lowered to $19 from $29 at Raymond James

Raymond James lowered the firm’s price target on Relay Therapeutics (RLAY) to $19 from $29 and keeps a...

5d ago

RLAY

Relay Therapeutics reports Q2 EPS (41c), consensus (47c)

Reports Q2 revenue $677,000, consensus $75,000. “It is an exciting time for Relay as we have initiated our...

6d ago

RLAY

Relay Therapeutics has positive read from Celcuity data, says Barclays

After Celcuity (CELC) announced topline results from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial evaluating...

16d ago

CELC

RLAY

Relay Therapeutics Reports Q2 2025 Financial Results and Progress

Relay Therapeutics Inc ( ($RLAY) ) has released its Q2 earnings. Here is a breakdown of the information...

6d ago

RLAY

Relay Therapeutics’ Phase 3 Study: A New Hope for Advanced Breast Cancer Treatment

Relay Therapeutics Inc (($RLAY)) announced an update on their ongoing clinical study. Relay Therapeutics Inc. is conducting a...

12d ago

RLAY

Claire Mazumdar Joins Relay Therapeutics as Director

Relay Therapeutics ( ($RLAY) ) just unveiled an announcement. On June 8, 2025, Jami Ruben resigned from the...

2M ago

RLAY

Relay Therapeutics Holds 2025 Annual Stockholder Meeting

Relay Therapeutics ( ($RLAY) ) has shared an update. On June 6, 2025, Relay Therapeutics held its 2025...

2M ago

RLAY

Relay Therapeutics Announces Lease Termination Agreement

An announcement from Relay Therapeutics ( ($RLAY) ) is now available. On June 3, 2025, Relay Therapeutics, Inc....

2M ago

RLAY

Relay Therapeutics announces updated data for RLY-2608 with Fulvestrant

Relay Therapeutics (RLAY) announced updated interim clinical data for RLY-2608, the first known investigational allosteric, pan-mutant and isoform-selective...

2M ago

RLAY

Relay Therapeutics price target lowered to $10 from $30 at Guggenheim

Guggenheim lowered the firm’s price target on Relay Therapeutics (RLAY) to $10 from $30 and keeps a Buy...

3M ago

RLAY

3 Best Stocks to Buy Now, 5/7/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

3M ago

ALAB

PRTH

Oncology stocks ‘bearing the brunt’ of Prasad news, says Oppenheimer

Oppenheimer says Vinay Prasad, who has reportedly been nominated to lead the FDA’s Center for Biologics Evaluation and...

3M ago

IDYA

NRIX

Relay Therapeutics: Awaiting Significant Catalysts Amidst Strong Cash Position and Pipeline Potential

Wells Fargo analyst Eva Fortea Verdejo has maintained their neutral stance on RLAY stock, giving a Hold rating...

3M ago

RLAY

Relay Therapeutics Extends Cash Runway and Advances Clinical Trials

Relay Therapeutics Inc ( ($RLAY) ) has released its Q1 earnings. Here is a breakdown of the information...

3M ago

RLAY

RLAY FAQ

What was Relay Therapeutics Inc’s price range in the past 12 months?

Relay Therapeutics Inc lowest stock price was $1.77 and its highest was $10.72 in the past 12 months.

What is Relay Therapeutics Inc’s market cap?

Relay Therapeutics Inc’s market cap is $577.58M.

When is Relay Therapeutics Inc’s upcoming earnings report date?

Relay Therapeutics Inc’s upcoming earnings report date is Nov 05, 2025 which is in 84 days.

How were Relay Therapeutics Inc’s earnings last quarter?

Relay Therapeutics Inc released its earnings results on Aug 07, 2025. The company reported -$0.41 earnings per share for the quarter, beating the consensus estimate of -$0.492 by $0.082.

Is Relay Therapeutics Inc overvalued?

According to Wall Street analysts Relay Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Relay Therapeutics Inc pay dividends?

Relay Therapeutics Inc does not currently pay dividends.

What is Relay Therapeutics Inc’s EPS estimate?

Relay Therapeutics Inc’s EPS estimate is -0.43.

How many shares outstanding does Relay Therapeutics Inc have?

Relay Therapeutics Inc has 172,411,400 shares outstanding.

What happened to Relay Therapeutics Inc’s price movement after its last earnings report?

Relay Therapeutics Inc reported an EPS of -$0.41 in its last earnings report, beating expectations of -$0.492. Following the earnings report the stock price went down -7.736%.

Which hedge fund is a major shareholder of Relay Therapeutics Inc?

Currently, no hedge funds are holding shares in RLAY

Relay Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-46.24%

Trailing 12-Months

Asset Growth

-5.66%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Relay Therapeutics Inc

Relay Therapeutics, Inc. (RLAY) is a biotechnology company primarily focused on transforming the drug discovery process by leveraging an innovative integration of computational and experimental approaches. The company operates within the pharmaceutical and biotech sectors, and its core products include small molecule therapies aimed at treating cancers and other genetic diseases. Relay Therapeutics employs a platform that combines computational physics, chemistry, and biology to predict and visualize protein motion, which guides the design of targeted therapies.

Relay Therapeutics (RLAY) Earnings & Revenues

Historic Earnings Reports

RLAY Stock 12 Month Forecast

Average Price Target

$11.44

▲(252.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","20":"$20","5.75":"$5.75","10.5":"$10.5","15.25":"$15.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$19.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.44,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$11.44</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,5.75,10.5,15.25,20],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.36,4.563076923076923,5.766153846153847,6.969230769230769,8.172307692307692,9.375384615384615,10.57846153846154,11.781538461538462,12.984615384615385,14.187692307692307,15.39076923076923,16.593846153846155,17.79692307692308,{"y":19,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.36,3.9815384615384612,4.603076923076923,5.224615384615385,5.846153846153847,6.4676923076923085,7.0892307692307694,7.71076923076923,8.332307692307692,8.953846153846154,9.575384615384616,10.196923076923078,10.81846153846154,{"y":11.44,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.36,3.332307692307692,3.3046153846153845,3.276923076923077,3.249230769230769,3.2215384615384615,3.193846153846154,3.166153846153846,3.1384615384615384,3.1107692307692307,3.083076923076923,3.0553846153846154,3.0276923076923077,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.99,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.79,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.55,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.84,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.67,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.12,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.47,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.41,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.47,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.29,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.18,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.52,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.36,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >